Component
Human ADP-stimulated platelet aggregation with shikimic acid
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Ex-vivo 2 mM shikimic acid decreased ADP-induced platelet aggregation.
Experimental context and source evidence
- evidence_access
- Primary indexed abstract reviewed; full results, tables and supplements not independently extracted.
- experimental_contrast
- {"intervention": "Shikimic acid at the endpoint-specific concentration", "comparator": "Matched stimulated blood without shikimic acid", "endpoint": "Ex-vivo 2 mM shikimic acid decreased ADP-induced platelet aggregation.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
- experimental_model
- Blood from 22 sedentary humans, exposed ex vivo to 0.1–2 mM shikimic acid.
- interpretation_status
- Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
- limitations
- No ingestion, clinical thrombosis measurement or direct receptor binding. PAC-1 is retained as an assay label, not a procaspase-targeting compound.
- plain_language
- Ex-vivo 2 mM shikimic acid decreased ADP-induced platelet aggregation.
- primary_references
- Anti-platelet and anti-thrombogenic effects of shikimic acid in sedentary population. | 2016 | DOI 10.1039/c6fo00927a | PMID 27480079 | https://pubmed.ncbi.nlm.nih.gov/27480079/ | https://doi.org/10.1039/c6fo00927a
- source_locator
- Reviewed reference lines 55-55; exact primary location described in quoted passage where extracted.
Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026) · lines 55–55
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Blood from 22 sedentary humans, exposed ex vivo to 0.1–2 mM shikimic acid. · source_derived_draft · unverified_draft
**Human blood was exposed outside the body.** Veach 2016 added 0.1–2 mM shikimic acid to blood from 22 sedentary participants. ADP-induced aggregation decreased at 2 mM, whereas collagen-induced aggregation did not significantly decrease. Flow cytometry recorded lower PAC-1 signal at 2 mM, CD62P at 1–2 mM, monocyte–platelet aggregates at 0.5–2 mM and CD31 at 1 mM. PAC-1 here is a platelet activation assay label; the abstract’s expansion as a procaspase-activating compound is not imported as a drug mechanism. This ex-vivo experiment is not an oral trial, direct P2Y12-binding assay or clinical thrombosis result. The millimolar exposures exceed the micromolar animal oral peaks cited above, without establishing any human equivalence. [Anti-platelet and anti-thrombogenic effects of shikimic acid in sedentary population.](https://pubmed.ncbi.nlm.nih.gov/27480079/)
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.